Primary Site >> Esophagus Cancer
Gene >> ERCC1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Polymorphisms in DNA repair genes and associations with cancer risk. PMID: 12496039 |
Ref: High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. PMID: 15173087 |
Ref: Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. PMID: 15737843 Ref: High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. PMID: 15788669 |
Ref: Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. PMID: 17163161 |
Ref: Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. PMID: 17607914 |
Ref: ZNRD1 might mediate UV irradiation related DNA damage and repair in human esophageal cancer cells by regulation of ERCC1. PMID: 18564169 Ref: Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. PMID: 18594004 Ref: Upregulation of ZNRD1 enhances cisplatin resistance in human esophageal cancer cells by regulation of ERCC1 and Bcl-2. PMID: 18645262 Ref: ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. PMID: 18769985 |
Ref: Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. PMID: 19270000 Ref: ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. PMID: 19421825 Ref: Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer. PMID: 19424628 Ref: Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. PMID: 19620936 |
Ref: Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma. PMID: 21286668 Ref: Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. PMID: 21586140 |
Ref: Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. PMID: 21956434 Ref: Effect of altered WIG-1 expression on DDP sensitivity in a DDP-resistant esophageal squamous cancer cell line. PMID: 22794122 |
Ref: ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. PMID: 23962907 |
Ref: Stem cell-like side populations in esophageal cancer: a source of chemotherapy resistance and metastases. PMID: 24021093 Ref: Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis. PMID: 24926347 Ref: ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy. PMID: 25042384 Ref: Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy. PMID: 25083297 Ref: ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China. PMID: 25191856 Ref: ERCC1 Expression in Non-Small Cell Lung and Esophageal Cancer. PMID: 25610304 |
Ref: A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. PMID: 25214541 Ref: Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. PMID: 25778705 Ref: Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-Analysis. PMID: 26426637 |
Ref: Genetic risk of subsequent esophageal cancer in lymphoma and breast cancer long-term survival patients: a pilot study. PMID: 26054330 Ref: A germline predictive signature of response to platinum chemotherapy in esophageal cancer. PMID: 26772957 Ref: A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy. PMID: 27100737 Ref: Effect of SNX-2112 on proliferation of esophageal cancer cells via regulation of excision repair cross-complementing 1, epidermal growth factor receptor, and p53 expression. PMID: 27420968 Ref: Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors. PMID: 27610644 Ref: Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study. PMID: 27741011 Ref: Tumor profiling of co-regulated receptor tyrosine kinase and chemoresistant genes reveal different targeting options for lung and gastroesophageal cancers. PMID: 28078044 |
Ref: Basis for molecular diagnostics and immunotherapy for esophageal cancer. PMID: 27838937 Ref: Predictive biomarkers for response of esophageal cancer to chemo(radio)therapy: A systematic review and meta-analysis. PMID: 29113666 Ref: Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer. PMID: 29163710 |
Ref: Clinical research of individualized therapy in advanced esophageal cancer based on the ERCC1 C8092A genotype. PMID: 30013648 |